BioGPS Featured Article- Multi-omic landscape of rheumatoid arthritis: re-evaluation of drug adverse effects | The Su Lab.

Adverse effects are one of many reasons why drug development is so expensive, and one reason why this week’s BioGPS Featured article is so interesting.

The drug development process typically looks something like this:

"Drug Evaluation Process" by Kernsters - Graph created based on information provided in Scientific American article, "Faster Evaluation of Vital Drugs". Licensed under CC BY-SA 3.0 via Wikipedia.
Drug Evaluation Process” by Kernsters – Graph created based on information provided in Scientific American article, “Faster Evaluation of Vital Drugs”. Licensed under CC BY-SA 3.0 via Wikipedia.

Not only does it take a long time to develop a drug, the risk of failure is quite high and each failure is costly. According to a study last year in Nature Biotechnology, about 10% of all indication development paths make it through phase I clinical trials (looking at safety) successfully. Because of the small numbers in Phase I, it’s hard to determine if observed side effects are general or patient-specific.

This week’s featured article aims to use multi-omics to “estimate the systemic impact (side/adverse events) of (novel) therapeutic targets.” The researchers focus on rheumatoid arthritis which is a very complex disease and also accounts for 20% of the Top 10 clinical trial failures in 2013 as ranked by the size of the writedowns associated with the trial outcome.

Now go check out the feature article, and see the awesome work that BioGPS users do.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s